Indazole-substituted 1,2,5-thiadiazolidine derivatives as inhibitors of protein tyrosine phosphatase 2 (PTPN2) for the treatment of cancer diseases

Abstract

Formula (I) as defined herein The compounds of TIFF2025538169000024.tif54153, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and combinations thereof, and methods of using them as inhibitors of protein tyrosine phosphatase 2 (PTPN2), are disclosed. These compounds are useful for treating cancers and diseases susceptible to PTPN2 inhibition.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No. 63 / 383,021, filed November 9, 2022, which is incorporated herein by reference in its entirety.

[0002] FIELD OF THE INVENTION This application discloses compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof and combinations thereof, and methods of their use as protein tyrosine phosphatase inhibitors. [Background technology]

[0003] Immune checkpoint blockade (ICB) is an innovative approach in immunotherapy that targets immune evasion mechanisms to improve clinical responses in cancer patients. For example, checkpoint inhibitor antibodies targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1), and their ligands (e.g., programmed cell death ligand 1 (PD-L1)) have been used in the treatment of multiple cancer types, significantly improving treatment and survival outcomes for patients with these malignancies.

[0004] However, the majority of patients undergoing ICB develop a treatment-refractory state or ultimately acquire resistance. In particular, alterations or defects in the interferon-γ (IFNγ) signaling pathway represent an important mechanism for clinical ICB resistance (Zaretsky, N. Engl. J. Med. 375, 819-829). IFNγ is a T cell-derived cytokine that directly restricts tumor growth by signaling through the Janus kinase / signal transducer and activator of transcription (JAK / STAT) pathway. Furthermore, IFNγ indirectly restricts tumor growth by promoting the upregulation of major histocompatibility complex class I (MHC-I), thereby presenting antigen (Ag) to T cells. In vivo CRISPR screening using a syngeneic mouse model revealed improvements in the IFNγ pathway in anti-PD-1–resistant tumors. These studies have confirmed that the aforementioned members of the IFNγ pathway (JAK1 / 2 and STAT1) and interferon-γ receptors (IFNGR1 / IFNGR2) are effective in resistance, in addition to newly identified negative regulators (e.g., PTPN2 and apelin receptor (APLNR)), and these represent new therapeutic targets (Charles Sinclair et al. Emerg Top Life Sci. (2021) 5 (5): 675-680).

[0005] Data compiled from an in vivo genetic screen using CRISPR-Cas9 genome editing to identify genes that cause resistance to checkpoint inhibitors confirmed that deletion of the protein tyrosine phosphatase (PTPN2) gene in tumor cells enhances the efficacy of immunotherapy. The PTPN2 gene encodes a protein tyrosine phosphatase that regulates various intracellular processes. Loss of PTPN2 in tumor cells enhances IFNγ signaling and antigen presentation to T cells, leading to proliferation arrest in response to cytokines. These data suggest that therapeutic inhibition of PTPN2 may enhance the efficacy of immunotherapies that trigger IFNγ responses (Manguso, Robert T et al. Nature vol. 547, 7664 (2017): 413-418).

[0006] Protein tyrosine phosphatase non-receptor type 2 (PTPN2), also known as T-cell protein tyrosine phosphatase (TCPTP), is a cellular member of the class 1 subfamily of phosphotyrosine-specific phosphatases that mediates multiple cellular regulatory processes by removing phosphate groups from tyrosine substrates. PTPN2 is ubiquitously expressed, but is most highly expressed in hematopoietic and placental cells (Mosinger, B. Jr. et al., Proc Natl Acad Sci USA (1992) 89:499-503). In humans, PTPN2 expression is posttranscriptionally regulated by the existence of two splice variants: a 45-kDa form containing a nuclear localization signal C-terminally upstream of the splice site, and a 48-kDa canonical form containing an ER retention motif C-terminally (Tillmann U. et al., Mol Cell Biol (1994) 14:3030-3040). The 45 kDa isoform can spontaneously translocate to the cytoplasm under certain cellular stress conditions. Both isoforms share an N-terminal phosphotyrosine phosphatase catalytic domain, and PTPN2 is a key negative regulator of the JAK-STAT pathway, directly controlling signal transduction through cytokine receptors. The PTPN2 catalytic domain shares 74% sequence identity with PTPN1 (also known as PTP1B) and has a similar enzymatic rate (Romsicki Y. et al., Arch Biochem Biophys (2003) 414:40-50).

[0007] Furthermore, T cell protein tyrosine phosphatase 2 (PTPN2) has been identified as an important negative regulator of T cell receptor (TCR) signaling, with a clear association between PTPN2 single nucleotide polymorphisms (SNPs) and autoimmune diseases (Wiede F et al., J Clin Invest. (2011);121(12):4758-4774). PTPN2 dephosphorylates and inactivates Src family kinases, regulating T cell responses. Deficiency of PTPN2 leads to TCR-dependent CD8 +PTPN2 has been shown to lower the in vivo threshold for T cell proliferation. Consistent with these findings, T cell-specific PTPN2-deficient mice have been shown to develop a variety of inflammatory and autoimmune diseases. Autoimmune diseases are associated with increased serum levels of proinflammatory cytokines and antinuclear antibodies, T cell infiltration into extralymphoid tissues, and liver disease. Furthermore, these data indicate that PTPN2 is a critical negative regulator of TCR signaling that sets the threshold for TCR-triggered naive T cell responses to prevent autoimmune and inflammatory diseases.

[0008] In addition to PTPN2, encoding the T cell PTP (TCPTP), as a susceptibility locus for autoimmune diseases, SNPs in PTPN2 have been linked to the development of type 1 diabetes, rheumatoid arthritis, and Crohn's disease. Furthermore, the PTPN2 variant rs1893217(C), associated with type 1 diabetes, is also associated with decreased PTPN2 expression in T cells (Florian Wiede J Clin Invest. 2011;121(12):4758-4774).

[0009] These findings suggest that PTPN2 inhibition is a promising therapeutic strategy to enhance the efficacy of cancer treatment regimens with ICB resistance. Summary of the Invention

[0010] The present disclosure relates to compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and combinations thereof, which are effective inhibitors of protein tyrosine phosphatases (e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1, also known as protein tyrosine phosphatase-1B (PTP1B))). The present invention further provides methods for treating, preventing, or ameliorating cancer, comprising administering to a subject in need thereof an effective amount of a PTPN2 / PTPN1 inhibitor of the present disclosure. In preferred embodiments, the compounds have a monocyclic core structure, compared to compounds described in the literature that contain a fused bicyclic core structure.

[0011] In some embodiments, the present application discloses inhibitors of protein tyrosine phosphatases (e.g., PTPN2 and / or PTP1B), comprising a compound of the present disclosure (e.g., a compound of Formula (I)). In other embodiments, the present application discloses a method of treating a disease or disorder (e.g., cancer, type 2 diabetes, obesity, metabolic disease, or any other disease, disorder, or condition that responds to PTPN2 or PTP1B inhibitory treatment), comprising administering an effective amount of a compound of the present disclosure (e.g., a compound of Formula (I)). These and other features of the present invention are broadly described in conjunction with the present disclosure.

[0012] A first aspect of the present invention is a compound of formula (I): [ka] wherein each independently represents: R 1 is selected from the group consisting of -H, alkyl, -OCH3, substituted alkyl, alkoxyl, amine, secondary amine, tertiary amine, halogen, aryl, -CH2CH3, -CN, -OCH3, cyclopropyl, cyclopropoxy, cyclohexyl, -CF3, -OH, -Ph, -CH2CH3, -N(CH3)2, -NHCH3, and cycloalkyl; R 2 -H, alkyl, -CN, -OCH 3、 Cycloalkyl, -CF3, -C(CH3)2R 7 , aryl, substituted alkyl, alkoxyl, —CH(CH3)2, —C(CH3)3, —OCF3, —OH, and benzyloxy; R 3 is selected from the group consisting of -H, alkyl, -OCH3, substituted alkyl, amine, secondary amine, tertiary amine, -CHF2, halogen, -CN, -OCH3, -N(CH3)2, -OCHF2, alkoxyl, -NHCH3, -OH, -CH2CH3, and morpholin-4-yl; R 4is selected from the group consisting of -H, alkyl, -CH2CH3, -OCH3, -OH, and -CF3; R 5 is selected from the group consisting of -H, cycloalkyl, alkyl, and substituted alkyl. The present invention provides at least one compound of the formula:

[0013] Additionally: 5-[6-fluoro-4-[[(6-methoxy-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-(6-fluoro-4-(((5-methoxypyridin-2-yl)amino)methyl)-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide; 5-[6-fluoro-4-[[(4-methoxy-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-[4-[[(4-cyclopropyl-2-pyridyl)amino]methyl]-6-fluoro-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-[6-fluoro-4-[[(4-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-(4-(((4,6-dimethylpyridin-2-yl)amino)methyl)-6-fluoro-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide; 5-(6-fluoro-4-(((4-methoxy-5-methylpyridin-2-yl)amino)methyl)-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide; 6-[[6-fluoro-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-1H-indazol-4-yl]methylamino]-4-methyl-pyridine-3-carbonitrile; 5-[6-fluoro-4-[[(4-methoxy-6-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; and 5-[6-Fluoro-4-[[(3-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one Disclosed is a compound selected from the group consisting of:

[0014] In some embodiments, the compound of Formula (I) is formulated as a pharmaceutically acceptable composition comprising a compound of Formula (I) and a pharmaceutically acceptable carrier.

[0015] Also disclosed herein is a method for treating cancer, comprising administering to a patient in need thereof an effective amount of a compound of formula (I) of the present disclosure in combination with another therapeutic agent. In some embodiments, the other therapeutic agent is an immunotherapeutic agent. For example, in some embodiments, the immunotherapeutic agent is an antibody.

[0016] Also disclosed herein is a method for treating cancer, comprising administering to a patient in need thereof an effective amount of a compound of the present disclosure (e.g., a compound of Formula (I)).

[0017] Further disclosed herein is a method for treating a metabolic disorder, comprising administering to a patient in need thereof an effective amount of a compound of the present disclosure (e.g., a compound of Formula (I)).

[0018] In some embodiments, the methods include treating cancer, hi some embodiments, the cancer includes pancreatic cancer, breast cancer, multiple myeloma, melanoma, or cancer of secretory cells.

[0019] Also disclosed are compositions for use in treating cancer in a patient in need thereof, the compositions comprising a compound of the present disclosure (e.g., a compound of Formula (I)) in combination with another therapeutic agent. In some embodiments, the other therapeutic agent is an immunotherapeutic agent. For example, in some embodiments, the immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody and an anti-PD-L1 antibody.

[0020] Further disclosed herein are compositions for use in treating a metabolic disorder in a patient in need thereof, wherein the composition comprises a compound of the present disclosure (e.g., a compound of Formula (I)). DETAILED DESCRIPTION OF THE INVENTION

[0021] The present disclosure relates to compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and combinations thereof that are effective as inhibitors of protein tyrosine phosphatases (e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and / or protein tyrosine phosphatase non-receptor type 1 (PTPN1, also known as protein tyrosine phosphatase-1B (PTP1B))). The present invention further provides methods for treating, preventing, or ameliorating cancer, comprising administering to a subject in need thereof an effective amount of a PTPN2 / PTPN1 inhibitor of the present disclosure. Compared to compounds described in the literature that contain a fused bicyclic core structure, the present compounds possess a monocyclic core structure in preferred embodiments.

[0022] definition chemical definition Definitions of specific functional groups and chemical terms are detailed below. Chemical elements are listed in accordance with the CAS version of the Periodic Table of the Elements, Handbook of Chemistry and Physics, 75 thEd., and specific functional groups are generally defined as described therein. Further, general principles of organic chemistry and specific functional groups and reactivities are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th Edition, John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd Edition, Cambridge University Press, Cambridge, 1987.

[0023] Abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulae set forth herein are constructed according to standard rules of atom valency known in the chemical arts.

[0024] The compounds described herein contain one or more asymmetric centers and may therefore exist in various isomers (e.g., enantiomers and / or diastereomers). For example, the compounds described herein may exist in the form of individual enantiomers, diastereomers, geometric isomers, or mixtures of stereoisomers, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers can be isolated from mixtures by methods known to those skilled in the art, such as chiral high-performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts, or preferred isomers can be prepared by asymmetric synthesis. See, for example, Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Wilen, Tables of Resolving Agents and Optical Resolutions p. 268 (EL Eliel, Ed., University of Notre Dame Press, Notre Dame, IN 1972). Additionally, the present disclosure encompasses compounds described herein as single isomers, substantially free of other isomers, or as mixtures of various isomers.

[0025] In the compositions described herein, the enantiomerically pure compound may be present together with other active or inactive ingredients. For example, a pharmaceutical composition containing an enantiomerically pure R-compound may contain, for example, about 90% excipients and about 10% enantiomerically pure R-compound.

[0026] The features and utilities of the inventions described in this disclosure may be more readily understood by those skilled in the art in view of the following definitions. Features of the invention described in separate embodiments may be combined to form a single embodiment or may be incorporated to comprise multiple embodiments. Embodiments identified herein as examples or preferred embodiments are illustrative and not limiting.

[0027] Unless the context clearly indicates otherwise, words referred to in the singular may also include the plural. For example, "a" and "an" may refer to either "one" or "one or more."

[0028] As used herein, the term "compound" refers to at least one compound. For example, a compound of formula (I) includes one compound of formula (I) and two or more compounds of formula (I).

[0029] Unless otherwise specified, any heteroatom with unsatisfied valences is assumed to have enough hydrogen atoms to satisfy the valences.

[0030] The definitions set forth herein take precedence over definitions set forth in any patents, patent applications, and / or published patent applications incorporated herein by reference.

[0031] Listed below are definitions of various terms used to describe this invention. These definitions apply to the terms as they are used throughout the specification, either individually or as part of a larger group (unless otherwise limited in specific instances).

[0032] Throughout the specification, groups and substituents may be chosen by one skilled in the art to provide stable moieties and compounds.

[0033] According to the practice used in the art, [ka] is used in structural formulas herein to represent the bond that is the point of attachment of a moiety or substituent to the core or backbone structure.

[0034] As used herein, the terms "halo" and "halogen" refer to F, Cl, Br, and I.

[0035] The term "cyano" refers to the group --CN.

[0036] The term "amino" refers to the group -NH2.

[0037] The term "oxo" refers to the group =O.

[0038] The term "alkyl" as used herein refers to both branched and straight-chain saturated aliphatic hydrocarbon groups, for example, having 1 to 12 carbon atoms, 1 to 6 carbon atoms, and 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and i-propyl), butyl (e.g., n-butyl, i-butyl, sec-butyl, and t-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. When a number appears as a subscript after the symbol "C," the subscript more specifically qualifies the number of carbon atoms that a particular group may contain. For example, "C 1-6 "Alkyl" means straight and branched chain alkyl groups having from 1 to 6 carbon atoms.

[0039] As used herein, the term "fluoroalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups substituted with one or more fluorine atoms. For example, "C 1-4 The term "fluoroalkyl" is meant to include C, C, C, and C alkyl groups substituted with one or more fluorine atoms. Representative examples of fluoroalkyl groups include, but are not limited to, -CF and -CHCF.

[0040] The term "cyanoalkyl" includes both branched and straight-chain saturated alkyl groups substituted with one or more cyano groups. For example, "cyanoalkyl" includes -CHCN, -CHCHCN, and -C 1-4 Cyanoalkyl is an example.

[0041] The term "aminoalkyl" includes both branched and straight-chain saturated alkyl groups substituted with one or more amino groups. For example, "aminoalkyl" includes -CH2NH2, -CH2CH2NH2, and C 1-4 Aminoalkyl is an example.

[0042] The term "hydroxyalkyl" includes both branched and straight-chain saturated alkyl groups substituted with one or more hydroxyl groups. For example, "hydroxyalkyl" includes -CHOH, -CHCHOH, and C 1-4 Hydroxyalkyl is an example.

[0043] The term "hydroxy-fluoroalkyl" includes both branched and straight-chain saturated alkyl groups substituted with one or more hydroxyl groups and one or more fluorine atoms. For example, "hydroxy-fluoroalkyl" includes -CHFCHOH, -CHCHFC(CH)OH, and -CHFCHOH. 1-4 Hydroxy-fluoroalkyl is an example.

[0044] As used herein, the terms "cycloalkyl," "carbocyclic," and "carbocyclyl" refer to a group derived from a non-aromatic monocyclic or polycyclic hydrocarbon molecule by removing one hydrogen atom from a saturated ring carbon atom. Representative examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. When a number appears as a subscript after the symbol "C," the subscript more specifically qualifies the number of carbon atoms that a particular cycloalkyl group may contain. For example, "C3-C6 cycloalkyl" refers to a cycloalkyl group having from 3 to 6 carbon atoms.

[0045] As used herein, the term "heterocycle" refers to an organic compound having a ring structure containing both carbon atoms and atoms other than carbon, such as oxygen and nitrogen.

[0046] The term "alkoxy," as used herein, refers to an alkyl group attached to the parent molecular moiety through an oxygen atom, for example, a methoxy group (-OCH). 1-3 "Alkoxy" means an alkoxy group having 1 to 3 carbon atoms.

[0047] The term "alkoxyalkyl," as used herein, refers to an alkoxy group (e.g., a methoxymethyl group (-CH2OCH3)) that is connected through an oxygen atom to an alkyl group that is bonded to the parent molecular moiety. For example, "C 2-4 "Alkoxyalkyl" refers to an alkoxyalkyl group having 2 to 4 carbon atoms, for example, -CH2OCH3, -CH2CH2OCH3, -CH2OCH2CH3, and -CH2CH2OCH2CH3.

[0048] As used herein, the term "amine" refers to a compound in which a nitrogen atom is directly bonded to several carbon atoms. Embodiments include derivatives of ammonia (-NH3), resulting from the stepwise replacement of three hydrogen atoms with hydrocarbon groups. Amines are classified as primary, secondary, or tertiary depending on the number of carbon atoms attached to the nitrogen atom. For example, primary amines have one carbon attached to the nitrogen (R-NH2), secondary amines have two carbons attached to the nitrogen and amine (R2-NH), and tertiary amines have three carbons attached to the nitrogen (R3-N), where R is an alkyl group.

[0049] As used herein, the term "heteroaryl" refers to a 5- to 10-membered aromatic heterocycle containing at least one carbon atom and at least one heteroatom selected from nitrogen, oxygen, and sulfur, and includes both monocyclic and bicyclic structures.

[0050] As used herein, the phrase "pharmaceutically acceptable" refers to compounds, substances, compositions, and / or dosage forms that are, within the scope of ordinary medical judgment, suitable for contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, and that are presenting a reasonable benefit / risk ratio.

[0051] The compound of formula (I) may be provided as an amorphous solid or a crystalline solid. The compound of formula (I) may be provided as an amorphous solid by lyophilization.

[0052] Additionally, solvates (e.g., hydrates) of compounds of formula (I) are also considered to be within the scope of the present invention. The term "solvate" refers to a physical association of a compound of formula (I) with one or more organic or inorganic solvent molecules. This physical association includes hydrogen bonding. In some cases, it is possible to isolate the solvate, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. "Solvate" includes both solution-phase and isolable solvates. Examples of solvates include hydrates, ethanolates, methanolates, isopropanolates, acetonitrile solvates, and ethyl acetate solvates. Methods of solvation are known in the art.

[0053] Various forms of prodrugs are well known in the art: a) The Practice of Medicinal Chemistry, Camille G. Wermuth et al., Ch 31, (Academic Press, 1996); b) Design of Prodrugs, edited by H. Bundgaard, (Elsevier, 1985); c) A Textbook of Drug Design and Development, P. Krogsgaard-Larson and H. Bundgaard, eds. Ch 5, pgs 113-191 (Harwood Academic Publishers, 1991); and d) Hydrolysis in Drug and Prodrug Metabolism, Bernard Testa and Joachim M. Mayer, (Wiley-VCH, 2003) is described in.

[0054] Additionally, once prepared, the compounds of formula (I) may be isolated and purified to obtain compositions containing 99% or greater of the compound of formula (I) ("substantially pure"), which are then used or formulated as described herein. Such "substantially pure" compounds of formula (I) are also considered herein to be part of the present invention.

[0055] By "stable compound" and "stable structure" is intended a compound that is sufficiently robust that it will not decompose upon isolation to a useful degree of purity from a reaction mixture, nor upon formulation into an efficacious therapeutic agent. The present invention is intended to embody stable compounds.

[0056] Those skilled in the art will also recognize that the compounds described and claimed herein as embodiments of the present invention may also exist in their "tautomeric forms." As used herein, tautomers refer to structural isomeric compounds that are readily interconvertible in rapid equilibrium. The process of interconversion is referred to herein as "tautomerization."

[0057] For example, an embodiment of an indazole tautomer is shown below. [ka] The above structures readily interconvert between the structures shown on the left and right.

[0058] A "therapeutically effective amount" is intended to include an amount of a compound of the invention alone, or in combination with the claimed compounds, or in combination with other active ingredients, that is effective to act as an inhibitor or to treat or ameliorate cancer.

[0059] As used herein, the term "treating" or "treatment" includes the treatment of a condition in a mammal, particularly a human, and includes (a) preventing the mammal from acquiring a condition that arises in that mammal if the mammal is prone to the condition, but particularly if the mammal has not yet been diagnosed as suffering from the condition; (b) inhibiting the condition, i.e., arresting the progression of the condition; and / or (c) palliating the condition, i.e., reducing the condition.

[0060] The compounds of the present invention are intended to encompass all isotopes of atoms contained in the compounds. Isotopes include atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium (D) and tritium (T). Isotopes of carbon include 13 C and 14 C. Isotopically labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art, or by methods analogous to those described herein, substituting the appropriate isotopically labeled reagent for the non-labeled reagent used elsewhere. For example, methyl (-CH3) also includes deuterated methyl groups (e.g., -CD3).

[0061] The term "pharmaceutically acceptable salts" refers to salts of active compounds prepared with relatively non-toxic acids or bases depending on the specific substituents in the compounds described herein. When a compound of the present disclosure contains a relatively acidic functional group, a base addition salt can be obtained by reacting the compound in a neutral state with a sufficient amount of the desired base in either a pure solvent or a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium salts, potassium salts, calcium salts, ammonium salts, organic amine salts, magnesium salts, or similar salts.

[0062] As defined herein, the terms "inhibition," "inhibiting," and the like, with respect to the interaction of a protein inhibitor (e.g., an antagonist), refer to negatively affecting (e.g., reducing) the activity or function of a protein compared to the activity or function of the protein in the absence of the inhibitor. In some embodiments, inhibition refers to the alleviation of a disease or disease symptom. In some embodiments, inhibition refers to the reduction of the activity of a signal transduction pathway or signal transduction pathway. Thus, at least in part, inhibition includes partial or complete inhibition of stimulation, reduction, suppression, or delay of activation, or inactivation, blunting, or downregulation of signal transduction or enzyme activity or protein amount. In some embodiments, inhibition refers to the reduction of the activity of a protein tyrosine phosphatase (e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) or protein tyrosine phosphatase non-receptor type 1 (PTP1B)). Thus, at least in part, inhibition can include partial or complete reduction in stimulation, decreased or diminished activation, or inactivation, blunting, or downregulation of signal transduction or enzymatic activity or amount of protein tyrosine phosphatase (e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) or protein tyrosine phosphatase non-receptor type 1 (PTP1B)).

[0063] "Patient" or "subject" refers to an organism suffering from or susceptible to a disease that can be treated by administration of a compound or pharmaceutical composition described herein. Examples include, but are not limited to, humans, other mammals, cows, rats, mice, dogs, monkeys, goats, sheep, cattle, deer, and other non-mammalian animals. In some embodiments, the patient is a human. In some embodiments, the patient is a domestic animal. In some embodiments, the patient is a dog. In some embodiments, the patient is a parrot. In some embodiments, the patient is a livestock animal. In some embodiments, the patient is a mammal. In some embodiments, the patient is a cat. In some embodiments, the patient is a horse. In some embodiments, the patient is a cow. In some embodiments, the patient is a dog. In some embodiments, the patient is a cat. In some embodiments, the patient is an ape. In some embodiments, the patient is a monkey. In some embodiments, the patient is a mouse. In some embodiments, the patient is a laboratory animal. In some embodiments, the patient is a rat. In some embodiments, the patient is a hamster. In some embodiments, the patient is a test animal. In some embodiments, the patient is a newborn animal. In some embodiments, the patient is a newborn. In some embodiments, the patient is a newborn mammal. In some embodiments, the patient is an elderly animal. In some embodiments, the patient is an elderly person. In some embodiments, the patient is an elderly mammal. In some embodiments, the patient is an elderly patient.

[0064] A "disease," "disorder," or "condition" refers to a condition of a patient or subject that can be treated by a compound, pharmaceutical composition, or method described herein. In some embodiments, the compounds and methods described herein include reducing or eliminating one or more symptoms of a disease, disorder, or condition, for example, by administering a compound of the present disclosure, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising a compound of the present disclosure or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

[0065] As used herein, the term "signal transduction pathway" refers to a series of interactions between cellular and any extracellular components (e.g., proteins, nucleic acids, small molecules, ions, lipids) that transmit a change in one component to one or more other components, which in turn transmit the change to other components, and the change is transmitted to other signal transduction pathway components as appropriate.

[0066] "Pharmaceutically acceptable excipients" and "pharmaceutically acceptable carriers" refer to substances that can be included in the compositions of the present disclosure to facilitate administration and absorption of an active agent by a subject without causing significant toxic side effects to the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline, lactated Ringer's solution, normal sucrose, normal glucose, binders, fillers, disintegrants, lubricants, coating agents, sweeteners, flavoring agents, salt solutions (e.g., Ringer's solution), alcohols, oils, gelatin, carbohydrates (e.g., lactose, amylose, or starch), fatty acid esters, hydroxymethylcellulose, polyvinylpyrrolidine, and coloring agents. Such preparations are sterilized and may contain, as needed, auxiliary substances (e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for adjusting osmotic pressure, buffers, coloring agents, and / or aromatic substances) that do not deleteriously react with the disclosed compounds. Those of skill in the art will recognize that other excipients are also useful in the present disclosure.

[0067] The term "formulation" is intended to include a formulation in which an encapsulating material as a carrier surrounds and combines with an active compound to form a capsule, which may or may not contain any other carriers other than the encapsulating material. Similarly, cachets and lozenges are included.Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid preparations suitable for oral administration.

[0068] As used herein, the term "administering" refers to oral administration, administration as a suppository, topical administration, intravenous administration, parenteral administration, intraperitoneal administration, intramuscular administration, intralesional administration, intrathecal administration, intracranial administration, intranasal administration, or subcutaneous administration to a subject, or implantation of a delayed-release device (e.g., a mini-osmotic pump). Administration can be by any route, including parenteral administration and administration via mucosal membranes (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or dermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial administration. Other delivery methods include, but are not limited to, the use of liposomal formulations, intravenous infusion, transdermal patches, and the like. By "in combination" is meant that a compound or composition described herein is administered simultaneously with, immediately before, or immediately after the administration of one or more additional therapeutic agents (e.g., anti-cancer, chemotherapeutic, or immunotherapeutic agents). The compounds or compositions described herein can be administered to a patient alone or in combination. Combination is intended to include simultaneous or sequential administration of the compounds or compositions alone or in combination (with one or more other compounds or drugs). Thus, the formulations can also be combined with other active substances, if desired (e.g., to reduce metabolic degradation).

[0069] The pharmaceutical compositions described herein can be prepared by any method known in pharmacology. Generally, such preparation methods include the steps of bringing a disclosed compound (the "active ingredient") into association with the carrier and / or one or more other accessory ingredients, and then, as necessary and / or desired, shaping and / or packaging the product into the desired single unit dose or multiple unit doses. Pharmaceutical compositions may be prepared, packaged, and / or sold in bulk in single unit doses and / or multiple unit doses. As used herein, a "unit dose" is a respective amount of pharmaceutical composition comprising a predetermined amount of the active ingredient. The amount of the active ingredient will generally be equal to the dose of the active ingredient that would be administered to a subject and / or an appropriate fraction of that dose (e.g., one-half or one-third of that dose).

[0070] Treatment method The present disclosure features compounds, compositions, and methods that include compounds of the present disclosure (e.g., compounds of Formula (I)). In some embodiments, the compounds, compositions, and methods of the present disclosure are used to prevent or treat a disease, disorder, or condition. Examples of diseases, disorders, or conditions include, but are not limited to, cancer, type 2 diabetes, metabolic syndrome, obesity, or metabolic disease.

[0071] cancer In some embodiments, the compounds of the present disclosure (e.g., compounds of Formula (I)) are used to treat cancer. As used herein, "cancer" refers to human carcinoma and carcinomas of carcinomas, non-carcinomas, adenocarcinomas (e.g., papillary adenocarcinoma), lymphoma, leukemia, melanoma, etc. (including solid carcinomas and lymphatic cancers), kidney, breast, lung, bladder, colon, ovary, prostate, pancreas, stomach, brain, head and neck, skin, uterus, testis, glioma, esophagus, liver, including hepatocellular carcinoma, B-cell acute lymphoblastic lymphoma, non-Hodgkin's lymphoma (e.g., Burkitt's lymphoma, small cell lymphoma, and large cell lymphoma), lymphomas, including Hodgkin's lymphoma, leukemia (including AML, ALL, and CML), and / or multiple myeloma. In yet another example, "cancer" refers to lung cancer, breast cancer, ovarian cancer, epithelial ovarian cancer, leukemia, lymphoma, melanoma, pancreatic cancer, non-epithelial carcinoma, bladder cancer, osteosarcoma, biliary tract cancer, adrenal cancer, salivary gland cancer, bronchial cancer, oral cancer, cancer of the oral cavity or pharynx, laryngeal cancer, kidney cancer, gynecological cancer, brain cancer, central nervous system cancer, peripheral nervous system cancer, cancer of the blood tissue, small intestine or appendix cancer, cervical cancer, colon cancer, esophageal cancer, stomach cancer, liver cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, prostate cancer, metastatic cancer, or epithelial carcinoma.

[0072] Examples of cancers that may be treated with the compounds, pharmaceutical compositions, or methods described herein include lymphoma, B-cell lymphoma, heavy chain disease, alpha chain disease, gamma chain disease, mu chain disease, Waldenstrom's macroglobulinemia, benign monoclonal gammopathy, non-epithelial malignancies, bladder cancer, osteosarcoma, brain cancer, cervical cancer, colon cancer, esophageal cancer, gastric cancer, head and neck cancer, kidney cancer, myeloma, thyroid cancer, leukemia, prostate cancer, breast cancer (e.g., ER-positive, ER-negative, chemotherapy-resistant, Herceptin-resistant, HER2-positive, HER2-negative ... The cancer may be HER2-positive, doxorubicin-resistant, tamoxifen-resistant, ductal carcinoma, lobular carcinoma, primary, metastatic), ovarian cancer, pancreatic cancer, liver cancer (e.g., hepatocellular carcinoma), lung cancer (e.g., non-small cell lung cancer, squamous cell lung carcinoma, adenocarcinoma, large cell lung carcinoma, small cell lung carcinoma, carcinoid, non-epithelial malignant tumor), glioblastoma multiforme, acoustic neuroma, retinoblastoma, astrocytoma, craniopharyngioma, hemangioblastoma, pineal tumor, ependymoma, oligodendroglioma, meningioma, glioma, or melanoma. Further examples include cancer of the thyroid, endocrine system, brain, breast, cervix, colon, head and neck, liver, kidney, lung, non-small cell lung cancer, melanoma, mesothelioma, ovarian cancer, sarcoma, stomach, uterine cancer or medulloblastoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma, neuroblastoma, glioma, glioblastoma multiforme, immunocytic amyloidosis, ovarian cancer, rhabdomyosarcoma, primary thrombocytosis, primary macroglobulinemia, primary brain tumor, cancer, malignant insulin-producing pancreatic insulinoma, malignant carcinoid, bladder cancer, precancerous lesions of the skin, testicular cancer, lymphoma, thyroid cancer, neuroblastoma, esophageal cancer, genitourinary cancer, malignant hypercalcemia, endometrial cancer, adrenocortical carcinoma, neoplasms of the endocrine or exocrine system of the pancreas, medullary thyroid carcinoma, melanoma, colorectal cancer, papillary thyroid carcinoma, and hepatocellular carcinoma.

[0073] A first aspect of the present invention is a compound of formula (I): [ka] wherein each independently represents: R 1is selected from the group consisting of -H, alkyl, -OCH3, substituted alkyl, alkoxyl, amine, secondary amine, tertiary amine, halogen, aryl, -CH2CH3, -CN, -OCH3, cyclopropyl, cyclopropoxy, cyclohexyl, -CF3, -OH, -Ph, -CH2CH3, -N(CH3)2, -NHCH3, and cycloalkyl; R 2 -H, alkyl, -CN, -OCH 3、 Cycloalkyl, -CF3, -C(CH3)2R 7 , aryl, substituted alkyl, alkoxyl, —CH(CH3)2, —C(CH3)3, —OCF3, —OH, and benzyloxy; R 3 is selected from the group consisting of -H, alkyl, -OCH3, substituted alkyl, amine, secondary amine, tertiary amine, -CHF2, halogen, -CN, -OCH3, -N(CH3)2, -OCHF2, alkoxyl, -NHCH3, -OH, -CH2CH3, and morpholin-4-yl; R 4 is selected from the group consisting of -H, alkyl, -CH2CH3, -OCH3, -OH, and -CF3; R 5 is selected from the group consisting of -H, cycloalkyl, alkyl, and substituted alkyl. At least one compound having the structure:

[0074] In certain embodiments of the compound of Formula I, R 1 is selected from the group consisting of -H, -CH3, -OCH3, and cyclopropyl; R 2 is selected from the group consisting of -H, -CH3, -CN, and -OCH3; R 3 is selected from the group consisting of -H, -CH3, and -OCH3; R 4 is selected from the group consisting of -H and -CH3.

[0075] In another embodiment of the compound of formula I, R 1 is cyclopropyl; R 2 is -H; R 3 is -H; R 4 is -H; R 5 is -H.

[0076] In certain embodiments of the compound of Formula I, R 1 is -OCH3; R 2 is alkyl; R 3 is -H; R 4 is -H; R 5 is -H.

[0077] In another embodiment of the compound of formula I, R 1 is -OCH3; R 2 is -H; R 3 is -H; R 4 is -H; R 5 is -H.

[0078] In certain embodiments of the compound of Formula I, R 1 is -OCH3; R 2 is -H; R 3 is alkyl; R 4 is -H; R 5 is -H.

[0079] In certain embodiments of the compound of Formula I, R 1 is -H; R 2 is -OCH3; R 3 is -H; R 4 is -H; R 5 is -H.

[0080] In another embodiment of the compound of formula I, R 1 is alkyl; R 2 is -CN; R 3 is -H; R 4 is -H; R 5 is -H.

[0081] In certain embodiments of the compound of Formula I, R 1 is -H; R 2 is -H; R 3 is -H; R 4 is alkyl; R 5 is -H.

[0082] In another embodiment of the compound of formula I, R 1 is -H; R 2 is -H; R 3 is -OCH3; R 4 is -H; R 5 is -H.

[0083] In certain embodiments of the compound of Formula I, the compound is: 5-[6-fluoro-4-[[(6-methoxy-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-(6-fluoro-4-(((5-methoxypyridin-2-yl)amino)methyl)-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide; 5-[6-fluoro-4-[[(4-methoxy-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-[4-[[(4-cyclopropyl-2-pyridyl)amino]methyl]-6-fluoro-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-[6-fluoro-4-[[(4-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-(4-(((4,6-dimethylpyridin-2-yl)amino)methyl)-6-fluoro-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide; 5-(6-fluoro-4-(((4-methoxy-5-methylpyridin-2-yl)amino)methyl)-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide; 6-[[6-fluoro-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-1H-indazol-4-yl]methylamino]-4-methyl-pyridine-3-carbonitrile; 5-[6-fluoro-4-[[(4-methoxy-6-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-[6-fluoro-4-[[(3-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one, or a pharmaceutically acceptable salt thereof.

[0084] In another embodiment, the present invention encompasses a pharmaceutical composition comprising a compound of formula (I) as set forth in claim 1, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

[0085] In certain embodiments, the present invention includes a method for treating cancer, comprising administering to a patient a therapeutically effective amount of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, wherein the cancer / disease is selected from human carcinoma, carcinoma of the epithelial carcinoma, carcinoma of the sarcoidosis, adenocarcinoma, papillary adenocarcinoma, lymphoma, leukemia, melanoma, solid tumor, cancer of the lymphatic system, kidney cancer, breast cancer, lung cancer, bladder cancer, colon cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, testicular cancer, glioma, esophageal cancer, liver cancer including hepatocellular carcinoma, B-cell acute lymphoblastic lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, small cell lymphoma, Hodgkin's lymphoma, leukemia, and multiple myeloma.

[0086] In another embodiment, the present invention comprises a method for treating cancer, comprising administering to a patient in need thereof an effective amount of a compound of Formula (I) in combination with another therapeutic agent.

[0087] In certain embodiments, the additional therapeutic agent is an immunotherapeutic agent.

[0088] In another embodiment, the immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody.

[0089] In certain embodiments, the method of treating cancer comprises administering to a patient in need of cancer treatment an effective amount of a pharmaceutically acceptable composition of a compound of Formula (I).

[0090] In another embodiment, the method of treating cancer is selected from radiation therapy, surgery, chemotherapy, or administration of a biopharmaceutical.

[0091] In some embodiments, a method of treating cancer is administering a biopharmaceutical, which is an agent that stimulates the immune system.

[0092] In another embodiment, a method of treating cancer comprises administering to a subject an inhibitor of DGKα and / or DGKζ, an antagonist of PD1 / PD-L1, and an antagonist of CTLA4.

[0093] These embodiments do not limit the scope of the invention.

[0094] Synthesis method The compounds of the present invention may be prepared from the methods and examples shown below, as well as from methods known to those skilled in the art. In each example below, the R group is defined as above in each formula unless otherwise specified. Optimum reaction conditions and reaction times may vary depending on the reactants used. Unless otherwise specified, solvents, temperatures, pressures, and other reaction conditions can be readily selected by one skilled in the art.

[0095] The intermediates used in the following syntheses are either commercially available or readily prepared by methods known to those skilled in the art. Reaction progress may be monitored by conventional methods, such as thin layer chromatography (TLC) or high performance liquid chromatography-mass spectrometry (HPLC-MS). Intermediates and products may be purified by methods known in the art, such as column chromatography, HPLC, preparative TLC, or preparative HPLC.

[0096] Preparation of Examples Preparation of synthetic intermediate (intermediate 2) Preparation of 7-(1,1-dioxide-4-oxo-1,2,5-thiadiazolidin-2-yl)-6-fluoro-2-(4-methoxybenzyl)-2H-indazole-4-carbaldehyde (Intermediate 2) as shown in Scheme 1 [ka]

[0097] Step 1: Synthesis of 4-bromo-6-fluoro-7-nitro-1H-indazole (1-2) To a round-bottom flask containing 4-bromo-6-fluoro-1H-indazole (10.00 g, 46.95 mmol) and sulfuric acid (100 mL), potassium nitrate (4.98 g, 49.30 mmol) dissolved in concentrated sulfuric acid (100 mL) was added dropwise at 0 °C and stirred at room temperature overnight. After the reaction was completed as monitored by LCMS, the mixture was poured into ice water (1.0 L), and a pale yellow precipitate formed. The mixture was filtered, and the solid was washed with water and dried to obtain the desired product. The crude product was purified by silica column chromatography (5% to 10% ethyl acetate / petroleum ether) to give 4-bromo-6-fluoro-7-nitro-1H-indazole (9.33 g, 35.88 mmol, 76.42% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ 14.23(s, 1H), 8.33(d, J=1.7Hz, 1H), 7.74(dd, J=11.5, 1.9Hz, 1H) Note: The desired isomer was identified by 2D NMR because no correlation was observed between the aromatic protons and the NH group of the pyrazole moiety.

[0098] Step 2: Synthesis of 4-bromo-6-fluoro-2-(4-methoxybenzyl)-7-nitro-2H-indazole (1-3) To a stirred mixture of 4-bromo-6-fluoro-7-nitro-1H-indazole (9.33 g, 35.88 mmol) in DCM (400 mL), 4-methoxybenzyl 2,2,2-trichloroacetimidate (12.68 g, 44.98 mmol) and TsOH (1.21 g, 7.02 mmol) were added at room temperature, and the mixture was stirred overnight at room temperature. LCMS showed that the starting material was completely consumed. The solution was diluted with DCM and washed with saturated sodium bicarbonate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (eluent: DCM) to give 4-bromo-6-fluoro-2-[(4-methoxyphenyl)methyl]-7-nitro-indazole (12.22 g, 32.15 mmol, 89.60% yield) as a yellow solid. MS: m / z: Theoretical: C 15 H 11 BrFN3O3[M+H] + 380; Observed: 380

[0099] Step 3: Synthesis of 4-bromo-6-fluoro-2-(4-methoxybenzyl)-2H-indazol-7-amine (1-4) To a stirred mixture of 4-bromo-6-fluoro-2-[(4-methoxyphenyl)methyl]-7-nitro-indazole (12.22 g, 32.15 mmol) in ethanol (200 mL) and water (20 mL), Fe (17.77 g, 318.26 mmol) and NH4Cl (17.22 g, 321.91 mmol) were added at room temperature and stirred at 80°C under a nitrogen atmosphere for 2 hours. LCMS showed the reaction was complete. The reaction mixture was filtered, the filtrate was concentrated, the ethanol was removed under reduced pressure, and the mixture was diluted with water (200 mL). The solution was extracted with ethyl acetate (3 x 200 mL). The combined organic layers were washed with brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (6% ethyl acetate / dichloromethane) to give 4-bromo-6-fluoro-2-[(4-methoxyphenyl)methyl]indazol-7-amine (10 g, 28.56 mmol, 88.82% yield) as a pink solid. MS: m / z: Theoretical value: C15 H 13 BrFNO[M+H] + 350; Observed: 350

[0100] Step 4: Synthesis of (4-bromo-6-fluoro-2-(4-methoxybenzyl)-2H-indazol-7-yl)glycine ethyl ester (1-5) To a stirred solution of 4-bromo-6-fluoro-2-[(4-methoxyphenyl)methyl]indazol-7-amine (7.5 g, 21.42 mmol) and 50% ethyl 2-oxoacetate in toluene (6.58 g, 32.13 mmol) in DMF (100 mL) was added TMSCl (6.8 mL, 53.54 mmol) at 0 °C and stirred at ambient temperature for 40 minutes. A solution of NaBHCN (3.37 g, 53.54 mmol) in DMF (20 mL) was slowly added to the above mixture at 0 °C. The resulting mixture was stirred at ambient temperature for 3 hours until the starting material was completely consumed. The mixture was quenched by the addition of saturated NH Cl (200 mL) at 0 °C. The solution was extracted twice with ethyl acetate, and the combined organic extracts were washed three times with brine. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by silica gel column chromatography (20% to 30% ethyl acetate / petroleum ether) to give ethyl 2-[[4-bromo-6-fluoro-2-[(4-methoxyphenyl)methyl]indazol-7-yl]amino]acetate (5.5 g, 12.60 mmol, 58.86% yield) as a pale yellow oil. MS: m / z: Theoretical value: C 19 H 19 BrFN3O3[M+H] + 436; Observed: 436

[0101] Step 5: Synthesis of N-(4-bromo-6-fluoro-2-(4-methoxybenzyl)-2H-indazol-7-yl)-N-sulfamoylglycine ethyl ester (1-6) To a stirred solution of ethyl 2-[[4-bromo-6-fluoro-2-[(4-methoxyphenyl)methyl]indazol-7-yl]amino]acetate (5.5 g, 12.61 mmol) in DMA (50 mL) was added a solution of sulfamoyl chloride (9.47 g, 81.94 mmol) in DMA (15 mL) at 0° C. The reaction mixture was stirred at ambient temperature overnight. LCMS showed complete consumption of the starting material. The mixture was diluted with ethyl acetate and washed seven times with brine until the DMA was completely consumed. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to give the product (6.7 g) as a light brown semi-solid. The crude product was used directly in the next step. MS: m / z: C 19 H 20 BrFN4O5S[M+H] + Theoretical: 515; Observed: 515

[0102] Step 6: Synthesis of 5-(4-bromo-6-fluoro-2-(4-methoxybenzyl)-2H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide (Intermediate 1) To a stirred solution of ethyl 2-[[4-bromo-6-fluoro-2-[(4-methoxyphenyl)methyl]indazol-7-yl]-sulfamoyl-amino]acetate (6.7 g, 13 mmol) in methanol (60 mL) was added 30% NaOMe / MeOH (14.03 g, 78.01 mmol) at 0 °C and stirred at ambient temperature for 2 h. After completion of the reaction as monitored by LCMS, the mixture was diluted with ethyl acetate and concentrated. The resulting suspension was dissolved in water (500 mL), diluted with ethyl acetate, acidified to pH = 3 with 1 N HCl, and extracted three times with ethyl acetate. The combined organic extracts were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The resulting residue was purified by reverse phase column chromatography to give 5-[4-bromo-6-fluoro-2-[(4-methoxyphenyl)methyl]indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one (4 g, 8.5237 mmol, 65.56% yield) as a pale yellow solid. MS: m / z: Theoretical value: C 17 H 14 BrFN4O4S [M+H]+ 469; Observations: 469

[0103] Step 7: Synthesis of 5-(6-fluoro-2-(4-methoxybenzyl)-4-vinyl-2H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide (1-7) To a stirred solution of 5-[4-bromo-6-fluoro-2-[(4-methoxyphenyl)methyl]indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one (2 g, 4.26 mmol) and tributyl(vinyl)stannane (4.05 g, 12.79 mmol) in DMA (20 mL) was added Pd(dba) (0.39 g, 0.43 mmol) and P(t-Bu)HBF (0.41 g, 0.85 mmol). The resulting mixture was evacuated and refilled with N three times. The mixture was then stirred at 100 °C overnight. LCMS showed complete consumption of the starting material. The reaction mixture is purified by reverse phase column (0.05% NH4HCO3 / water and MeCN) to give 5-[6-fluoro-2-[(4-methoxyphenyl)methyl]-4-vinyl-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one (1.1 g, 2.64 mmol, 61.98% yield) as a yellow solid. MS: m / z: Theoretical: C 19 H 17 FN4O4S [M+H] + 417; Observed: 417

[0104] Step 8: Synthesis of 7-(1,1-dioxide-4-oxo-1,2,5-thiadiazolidin-2-yl)-6-fluoro-2-(4-methoxybenzyl)-2H-indazole-4-carbaldehyde (Intermediate 2) To a stirred solution of 5-[6-fluoro-2-[(4-methoxyphenyl)methyl]-4-vinyl-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one (1.1 g, 2.64 mmol), NMO (0.62 g, 5.28 mmol), and citric acid (1.11 g, 5.28 mmol) in a mixture of tert-butanol (10 mL) and water (10 mL) was added KOsO (0.09 g, 0.26 mmol) at room temperature. The mixture was stirred at room temperature for 2 hours, and LCMS showed that the starting material was completely converted to the intermediate. NaIO (1.69 g, 7.92 mmol) was then added in portions to the mixture at 0 °C. The resulting mixture was stirred at room temperature for 2 hours, and LCMS showed that the reaction was complete. The reaction mixture was diluted with water (50 mL) and extracted seven times with ethyl acetate. The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting residue was purified by reverse-phase column chromatography (0.05% NH4HCO3 / water and MeCN) to afford 6-fluoro-2-[(4-methoxyphenyl)methyl]-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)indazole-4-carbaldehyde (600 mg, 1.43 mmol, 54.28% yield) as a yellow solid. MS: m / z: Theoretical: C 18 H 15 FN4O5S [M+H] + 419; Observed: 419

[0105] Example 1: 5-[6-fluoro-4-[[(6-methoxy-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one [ka] [ka]

[0106] Step 1: Synthesis of 5-(6-fluoro-2-(4-methoxybenzyl)-4-(((6-methoxypyridin-2-yl)amino)methyl)-2H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide (2-1) To a stirred solution of 6-fluoro-2-[(4-methoxyphenyl)methyl]-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)indazole-4-carbaldehyde (Intermediate 2, 60 mg, 0.14 mmol) and 6-methoxypyridin-2-amine (21.36 mg, 0.17 mmol) in DCM (5 mL) was added trimethylsilyl trifluoromethanesulfonate (63.89 mg, 0.28 mmol) at 0° C. and stirred at room temperature for 1 h. NaBH(OAc)3 (27.53 mg, 0.29 mmol) was added to the above mixture at 0° C. The reaction mixture was further stirred at room temperature for 2 h. After the reaction was complete as monitored by LCMS, the mixture was diluted with DCM (10 mL) and concentrated under reduced pressure. The resulting residue was purified by reverse-phase column chromatography (0.05% NH4HCO3 / water and MeCN) to give 5-[6-fluoro-1-[(4-methoxyphenyl)methyl]-4-[[(6-methoxy-2-pyridyl)amino]methyl]indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one (50 mg, 0.095 mmol, 66.21% yield) as a pale yellow solid. MS: m / z: Theoretical value: C 24 H 23 FN6O5S [M+H] + 527; Observations: 527

[0107] Step 2: Synthesis of 5-[6-fluoro-4-[[(6-methoxy-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one (2-2) To a solution of 5-[6-fluoro-1-[(4-methoxyphenyl)methyl]-4-[[(6-methoxy-2-pyridyl)amino]methyl]indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one (50 mg, 0.09 mmol) in DCE (2 mL) was added TFA (2 mL) at room temperature and stirred at 60° C. for 4 hours. After the reaction was complete as monitored by LCMS, the mixture was concentrated. The resulting residue was purified by reverse-phase column chromatography (0.05% NH4HCO3 / water and MeCN) and further purified by preparative HPLC to give 5-[6-fluoro-4-[[(6-methoxy-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one (14.5 mg, 0.03 mmol, 37.08% yield) as a white solid. MS: m / z: Theoretical value: C 16 H 15 FN6O4S[M+H] + Observations: 407; 1 H NMR (400MHz, DMSO-d6) δ 13.28(s, 1H), 8.33(d, J=3.8Hz, 1H), 7.58-7.13(m, 2H), 7.01(d, J=11.0Hz, 1H), 6.09(dd, J=7.9, 3.9Hz, 1H), 5.90(dd, J=7.8, 3.9Hz, 1H), 4.77(s, 2H), 4.45(d, J=3.8Hz, 2H), 3.66(d, J=3.0Hz, 3H) Preparative HPLC purification conditions: Column: SunFire Prep C18 OBD column, 19*150mm, 5μm; Mobile phase A: water (0.1% FA), Mobile phase B: ACN; Flow rate: 60mL / min; Gradient: 40% B to 60% B for 6.5 min, followed by 60% B; Wavelength: 254 / 210nm

[0108] Example 2: 5-(6-fluoro-4-(((5-methoxypyridin-2-yl)amino)methyl)-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide [ka] The title compound was obtained as a white solid (11.53% overall yield) by following the preparation of Example 1, but using 5-methoxypyridin-2-amine in Step 1. MS: m / z: C 16 H 15 FN6O4S [M+H] + Theoretical: 407; Observed: 407; 1 H NMR (400MHz, DMSO-d6) δ 13.26(s, 1H), 8.59(s, 1H), 8.26(s, 1H), 7.70(dd, J=9.7, 2.8Hz, 1H), 7.54(d, J=2.9Hz, 1H), 7.13-6.98(m, 2H), 4.85(s, 2H), 4.17(s, 2H), 3.77(s, 3H) Preparative HPLC purification conditions: Column: HALO C18, 3.0*30mm, 2.0µm; Mobile phase A: Water / 0.05% TFA, Mobile phase B: ACN / 0.05% TFA; Flow rate: 1.5000L / min; Gradient: 5%B to 40%B in 1.69 minutes, then 40%B to 95%B in 0.60 minutes, then 95%B for 0.5 minutes; Wavelength: 254nm

[0109] Example 3: 5-[6-fluoro-4-[[(4-methoxy-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one [ka] The title compound was obtained as a white solid (21.62% overall yield) by following the preparation of Example 1, except that 4-methoxypyridin-2-amine hydrochloride was used in Step 1. MS: m / z: C 16 H 15 FN6O4S[M+H] + Theoretical: 407; Observed: 407; 1H NMR (400MHz, DMSO-d6) δ 13.25(s, 1H), 12.79(s, 1H), 8.75(s, 1H), 8.26(s, 1H), 7.87(d, J=7.2Hz, 1H), 7.06(d, J=11.5Hz, 1H), 6.58(dd, J=7.2, 2.4Hz, 1H), 6.48(d, J=2.4Hz, 1H), 4.89(d, J=5.6Hz, 2H), 4.12(s, 2H), 3.90(s, 3H) Preparative HPLC purification conditions: SunFire Prep C18 OBD column, 19*150mm, 5μm; Mobile phase A: water (0.05% TFA), Mobile phase B: ACN; Flow rate: 25mL / min; Gradient: 20% B to 40% B in 5.3 minutes, followed by 40% B; Wavelength: 254 / 210nm

[0110] Example 4: 5-[4-[[(4-cyclopropyl-2-pyridyl)amino]methyl]-6-fluoro-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one [ka] The title compound was obtained as a white solid (7.78% overall yield) by following the preparation of Example 1, using 4-cyclopropylpyridin-2-amine in Step 1. MS: m / z: C 18 H 17 FN6O3S[M+H] + Theoretical: 417; Observed: 417; 1 H NMR (400MHz, DMSO-d6+D2O) δ 8.28(d, J=5.0Hz, 1H), 7.77-7.67(m, 1H), 7.07(dd, J=11.5, 4.2Hz, 1H), 6.77(d, J=11.4Hz, 1H), 6.54(t, J=6.8Hz, 1H), 4.88(d, J=5.7Hz, 2H), 4.15(s, 2H), 2.10-1.90(m, 1H), 1.30-1.10(m, 2H), 1.00-0.70(m, 2H) Preparative HPLC purification conditions: SunFire Prep C18 OBD column, 19*150mm, 5μm; Mobile phase A: water (0.1% FA), Mobile phase B: ACN; Flow rate: 20mL / min; Gradient: 10% B to 25% B for 6 minutes, followed by 25% B; Wavelength: 210 / 254nm

[0111] Example 5: 5-[6-fluoro-4-[[(4-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one [ka] The title compound was obtained as a white solid (10.71% overall yield) by following the preparation of Example 1, but using 4-methylpyridin-2-amine in Step 1. MS: m / z: C 16 H 15 FN6O3S[M+H] + Theoretical: 391; Observed: 391; 1 H NMR (400MHz, DMSO-d6) δ 13.28(s, 1H), 8.99(s, 1H), 8.26(s, 1H), 7.87(d, J=6.5Hz, 1H), 7.20-6.89(m, 2H), 6.80(d, J=6.5Hz, 1H), 4.88(d, J=5.5Hz, 2H), 4.14(s, 2H), 2.35(s, 3H) Preparative HPLC purification conditions: SunFire Prep C18 OBD column, 19*150mm, 5μm; Mobile phase A: water (0.1% FA), Mobile phase B: ACN; Flow rate: 25mL / min; Gradient: 50%B~70%B in 5.3 minutes, followed by 70%B; Wavelength: 210 / 254nm

[0112] Example 6: 5-(4-(((4,6-dimethylpyridin-2-yl)amino)methyl)-6-fluoro-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide [ka] The title compound was obtained as a white solid (13.75% overall yield) by following the preparation of Example 1, but using 4,6-dimethylpyridin-2-amine in Step 1. MS: m / z: C 17 H 18 FN6O3S[M+H] + Theoretical: 405; Observed: 405; 1 H NMR (500MHz, DMSO-d6) δ 13.28(s, 1H), 8.99(s, 1H), 8.26(s, 1H), 7.21(s, 1H), 7.11(s, 1H), 7.07-6.98(m, 2H), 6.74(br s, 1H), 6.67-6.55(m, 1H), 4.89(br d, J=5.2Hz, 2H), 4.11(br s, 2H), 2.40(s, 3H), 2.27(s, 3H) Preparative HPLC purification conditions: XBridge C18 column, 19*200mm, 5μm; Mobile phase A: ACN / H2O (5:95, containing 10mM AA); Mobile phase B: ACN / H2O (95:5, containing 10mM AA); Flow rate: 20mL / min; Gradient: Elute at 0%B~40%B for 20 minutes, then elute at 40%B; Wavelength: 220nm

[0113] Example 7: 5-(6-fluoro-4-(((4-methoxy-5-methylpyridin-2-yl)amino)methyl)-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide [ka] The title compound was obtained as a white solid (23.80% overall yield) by following the preparation of Example 1, but using 4-methoxy-5-methylpyridin-2-amine in Step 1. MS: m / z: C 17 H 17 FN6O4S [M+H] + Theoretical: 421; Observed: 421; 1H NMR (500MHz, DMSO-d6) δ 13.28(s, 1H), 8.99(s, 1H), 8.23(s, 1H), 7.70(s, 1H), 7.22-6.94(m, 2H), 4.89-4.82(m, 2H), 4.09(s, 2H), 3.88(s, 3H), 1.99(s, 3H) Preparative HPLC purification conditions: XBridge C18 column, 19*200mm, 5μm; Mobile phase A: ACN / H2O (5:95, containing 10mM AA); Mobile phase B: ACN / H2O (95:5, containing 10mM AA); Flow rate: 20mL / min; Gradient: Elute at 0%B~40%B for 20 minutes, then elute at 40%B; Wavelength: 220nm

[0114] Example 8: 6-[[6-fluoro-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-1H-indazol-4-yl]methylamino]-4-methyl-pyridine-3-carbonitrile [ka] The title compound was obtained as a white solid (17.62% overall yield) according to the preparation of Example 1, using 6-amino-4-methyl-pyridine-3-carbonitrile in Step 1. MS: m / z: C 17 H 14 FN7O3S [M+H] + Theoretical: 416; Observed: 416; 1 H NMR (400MHz, DMSO-d6) δ 13.29(s, 1H), 8.95-7.77(m, 3H), 6.93(d, J=11.3Hz, 1H), 6.56(s, 1H), 4.86(s, 2H), 4.41(s, 2H), 2.28(d, J=4.4Hz, 3H) Preparative HPLC purification conditions: Aeris PEPTIDE 5um XB-C18 Axia, 21.2mm 254 / 210nm

[0115] Example 9: 5-[6-fluoro-4-[[(4-methoxy-6-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one [ka] [ka]

[0116] Step 1: To a stirred mixture of 6-fluoro-2-[(4-methoxyphenyl)methyl]-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)indazole-4-carbaldehyde (Intermediate 2, 50 mg, 0.12 mmol) and 4-methoxy-6-methyl-pyridin-2-amine (25 mg, 0.18 mmol) in DCE (4 mL) was added Ti(i-PrO) (68 mg, 0.24 mmol) and stirred at room temperature for 1 hour. NaBHCN (31 mg, 0.48 mmol) was added to the mixture at 0 °C and stirred at room temperature for 1 hour. After the reaction was completed as monitored by LCMS, the mixture was concentrated. The resulting residue was purified by reverse phase column chromatography to give 5-[6-fluoro-4-[[(4-methoxy-6-methyl-2-pyridyl)amino]methyl]-2-[(4-methoxyphenyl)methyl]indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one (44 mg, 0.08 mmol, 68% yield) as a pale yellow solid. MS: m / z: C 25 H 25 FN6O5S [M+H] + Theoretical: 541; Observed: 541

[0117] Step 2: The title compound was obtained as a white solid (10.00% yield) by following Step 2 of the preparation of Example 1. MS: m / z: C 17 H 17 FN6O4S [M+H] + Theoretical: 421; Observed: 421;1 H NMR (400MHz, DMSO-d6) δ 13.24(s, 1H), 12.68(s, 1H), 8.29(s, 2H), 7.08(d, J=11.5Hz, 1H), 6.50(s, 1H), 6.35(s, 1H), 4.92(d, J=5.9Hz, 2H), 4.12(d, J=4.9Hz, 2H), 3.86(s, 3H), 2.40(s, 3H) Preparative HPLC purification conditions: SunFire Prep C18 OBD column, 19*150mm, 5μm; Mobile phase A: water (0.05% TFA), Mobile phase B: ACN; Flow rate: 60mL / min; Gradient: 40%B~60%B in 6.5 minutes, followed by 60%B; Wavelength: 254 / 210nm

[0118] Example 10: 5-[6-fluoro-4-[[(3-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one [ka] The title compound was obtained as a white solid (6.21% overall yield) by following the preparation of Example 9, using 3-methylpyridin-2-amine in Step 1. MS: m / z: C 16 H 15 FN6O3S [M+H] + Theoretical: 391; Observed: 391; 1 H NMR (400MHz, DMSO-d6) δ 13.26(s, 1H), 8.59(s, 1H), 8.26(s, 1H), 8.84-8.65(m, 2H), 6.92-6.71(m, 2H), 4.85(s, 2H), 4.06(s, 2H), 2.23(s, 3H) Preparative HPLC purification conditions: SunFire Prep C18 OBD column, 19*150mm, 5μm; Mobile phase A: water (0.05% TFA), Mobile phase B: ACN; Flow rate: 60mL / min; Gradient: 5% B to 20% B in 6.5 minutes, followed by 20% B; Wavelength: 254 / 210nm

[0119] Example compounds prepared by the above procedures are listed in Table 1. [Table 1] [Table 2]

[0120] Biological assays The pharmacological properties of the compounds of this invention may be confirmed by a number of biological assays known in the art. The following biological assays have been carried out with the compounds of this invention. Data for suitable embodiments are listed in Table 2.

[0121] PhosphoSens assay The PhosphoSens® Kinase Assay was performed as described by the manufacturer (AssayQuant Technologies, Marlborough, MA). Briefly, 1000x DMSO solutions of compounds were prepared in a 384-well reagent plate by serially diluting 3x with a 10mM DMSO stock solution. 50nL of the serially diluted compound solution was then added to the corresponding wells of a 384-well assay plate. 40mL of a 1.25x diluted substrate (AQT0264) / 1x assay buffer (50mM HEPES pH 7.5, 500µM EGTA, 10nM MgCl2, 0.01% Brij-35, 1% glycerol, 1mM DTT, and 0.2mg / mL BSA) was added to each well of the assay plate, resulting in a final substrate concentration of 20µM. Finally, 10mL of a 5x diluted PTPN2 enzyme stock solution was added to each well of the assay plate, resulting in a final enzyme concentration of 150pM. 360nm(λ ex 360) excitation wavelength and 480 nm (λ emThe fluorescence intensity at wavelength 480 was measured every 71 seconds at room temperature for 1 hour using a Synergy H4 plate reader (BioTek Instruments / Agilent Technologies, Winooski, VT), and a reaction progress curve was generated.

[0122] Phosphatase activity assay using DiFMUP as a substrate The PTPN2 biochemical assay was performed as follows. A 5x stock solution of human PTPN2 (SRP5075, MilliporeSigma, Burlington, MA) and a 1.25x stock solution of DiFMUP (D6567, ThermoFisher Scientific, Waltham, MA) were prepared in 1x reaction buffer containing 50 mM HEPES, pH 7.4, 1 mM EDTA, 150 mM NaCl, 0.2 mg / mL BSA, 100 U / mL catalase, and 10 mM DTT. 40 mL of DiFMUP substrate solution (25 mM final concentration) was added to a 384-well microtiter plate (Corning 3574, white, non-binding surface) containing 0.05 mL of serially diluted test compound in DMSO. The reaction was initiated by adding the enzyme solution (10 mL) to a final PTPN2 concentration of 0.15 nM, and the reaction was monitored at room temperature using a BioTek Synergy HTX plate reader (Agilent Technologies, Santa Clara, CA). ex 360 / λ em The activity was monitored at 460°C every 105 seconds for 60 minutes. The initial linear portion of the progress curve was fitted with a linear equation to determine the slope, and the value of the control treated with no inhibitor was defined as 100% activity, and the inhibition rate (%) was calculated. The IC value of each compound was calculated by fitting the inhibition rate (%)-compound concentration curve using Dotmatics software (Dotmatics, Bishops Stortford, Hertfordshire, England). 50 got the value.

[0123] Cell Proliferation Assay Protocol B16-F10 cells (ATCC, Manassas, VA, #CRL-6475) were cultured in DMEM basal medium (ThermoFisher Scientific, #11995-040) supplemented with 10% heat-inactivated FBS (ThermoFisher Scientific, Waltham, MA, #16140-071) and 1% penicillin / streptomycin (ThermoFisher Scientific, #15140-122). Cells were seeded into two opaque white 384-well tissue culture-treated microplates (PerkinElmer, Waltham, MA, #6007688) at a density of 100 cells / well in a total volume of 20 μL and incubated overnight at 37°C and 5% CO. The compound solution (30 nL) in DMSO was then transferred from the original plate to the desired wells using an Echo 650 acoustic liquid handler (Beckman Coulter, Indianapolis, IN). Negative control wells received DMSO alone (30 nL, final concentration 0.15%). The plates were returned to the incubator, and after 1 h, the cells were treated with either 5 μL of basal medium or 5 μL of basal medium containing 50 ng / mL of mouse IFN-γ recombinant protein (R&D Systems, Minneapolis, MN, #485-MI / CF, final concentration 10 ng / mL) using an ASSIST automated dispenser (INTEGRA Biosciences, Hudson, NH). The plates were incubated at 37°C for 4 days, and then cell proliferation assays were performed using CellTiter-Glo reagent (Promega, Madison, WI, #G7573, 25 μL / well). The luminescence signal intensity was measured 15 minutes after addition of the CellTiter-Glo reagent using an EnVision 2105 plate reader (PerkinElmer) and analyzed using the Dotmatics software platform to calculate the IC50 values ​​of the compounds. Cell Titer-Glo reagent inhibited growth in the absence of IFNγ, identifying off-target compounds that caused cytotoxicity.

[0124] Phospho-STAT1 Assay Protocol B16-F10 cells (ATCC, Manassas, VA, #CRL-6475) were cultured in DMEM basal medium (ThermoFisher Scientific, #11995-040) supplemented with 10% heat-inactivated FBS (ThermoFisher Scientific, Waltham, MA, #16140-071) and 1% penicillin / streptomycin (ThermoFisher Scientific, #15140-122). Cells were seeded into opaque white 384-well tissue culture-treated microplates (PerkinElmer, Waltham, MA, #6007688) at a density of 10,000 cells / well in a total volume of 20 μL and incubated overnight at 37°C and 5% CO. DMSO solutions (30 nL) of compounds were then transferred from the original plate to the appropriate wells using an Echo 650 acoustic liquid handler (Beckman Coulter, Indianapolis, IN). Negative control wells received DMSO alone (30 nL, final concentration 0.15%). The plates were returned to the incubator, and after 1 h, cells were treated with either 5 μL of basal medium or 5 μL of basal medium containing 500 ng / mL of mouse IFN-γ recombinant protein (R&D Systems, Minneapolis, MN, #485-MI / CF, final concentration 100 ng / mL) using an ASSIST automated dispenser (INTEGRA Biosciences, Hudson, NH). Plates were incubated at 37°C for 1 h, and phosphorylated STAT1 protein levels were assayed using the Phospho-STAT1 (Tyr701) HTRF kit (Cisbio, Bedford, MA, #63ADK026PEH) according to the manufacturer's instructions. After 24 h, HTRF signal intensity was measured with an EnVision 2105 plate reader (PerkinElmer) and analyzed using the Dotmatics software platform to determine the IC of compounds. 50 values ​​were calculated.

[0125] Biological Assay Data Table 2 summarizes the biological assay data for the examples / embodiments prepared. IC50 For data, a high concentration DDT assay and / or a DiFMUP substrate assay were used. Either assay may be utilized by those skilled in the art. Rows or columns marked with double asterisks represent the IC obtained. 50 Indicates that there is one value or aspect of. [Table 3] [Table 4]

Claims

1. The following structure: 【Chemistry 1】 wherein each independently represents R 1 is -H, alkyl, -OCH 3 , substituted alkyl, alkoxyl, amine, secondary amine, tertiary amine, halogen, aryl, -CH 2 CH 3 , -CN, -OCH 3 , cyclopropyl, cyclopropoxy, cyclohexyl, -CF 3 , -OH, -Ph, -CH 2 CH 3 , -N(CH 3 ) 2 , -NHCH 3 and cycloalkyl; R 2 -H, alkyl, -CN, -OCH 3、 Cycloalkyl, -CF 3 , -C(CH 3 ) 2 R 7 , aryl, substituted alkyl, alkoxyl, -CH(CH 3 ) 2 , -C(CH 3 ) 3 , -OCF 3 , —OH, and benzyloxy; R 3 is -H, alkyl, -OCH 3 , substituted alkyl, amine, secondary amine, tertiary amine, -CHF 2 , halogen, -CN, -OCH 3 , -N(CH 3 ) 2 , -OCHF 2 , alkoxyl, -NHCH 3 , -OH, -CH 2 CH 3 and morpholin-4-yl; R 4 is -H, alkyl, -CH 2 CH 3 , -OCH 3 , -OH, and -CF 3 selected from the group consisting of: R 5 is selected from the group consisting of -H, cycloalkyl, alkyl, and substituted alkyl. A compound having the formula:

2. During the ceremony, R 1 -H, -CH 3 , -OCH 3 and cyclopropyl; R 2 -H, -CH 3 , -CN, and -OCH 3 selected from the group consisting of: R 3 -H, -CH 3 , and -OCH 3 selected from the group consisting of: R 4 -H and -CH 3 selected from the group consisting of 2. The compound of claim 1.

3. During the ceremony, R 1 is cyclopropyl; R 2 is -H; R 3 is -H; R 4 is -H; R 5 is -H, 2. The compound of claim 1.

4. During the ceremony, R 1 But, -OCH 3 and; R 2 is alkyl; R 3 is -H; R 4 is -H; R 5 is -H, 2. The compound of claim 1.

5. During the ceremony, R 1 But, -OCH 3 and; R 2 is -H; R 3 is -H; R 4 is -H; R 5 is -H, 2. The compound of claim 1.

6. During the ceremony, R 1 But, -OCH 3 and; R 2 is -H; R 3 is alkyl; R 4 is -H; R 5 is -H, 2. The compound of claim 1.

7. During the ceremony, R 1 is -H; R 2 But, -OCH 3 and; R 3 is -H; R 4 is -H; R 5 is -H, 2. The compound of claim 1.

8. During the ceremony, R 1 is alkyl; R 2 is -CN; R 3 is -H; R 4 is -H; R 5 is -H, 2. The compound of claim 1.

9. During the ceremony, R 1 is -H; R 2 is -H; R 3 is -H; R 4 is alkyl; R 5 is -H, 2. The compound of claim 1.

10. During the ceremony, R 1 is -H; R 2 is -H; R 3 But, -OCH 3 and; R 4 is -H; R 5 is -H, 2. The compound of claim 1.

11. below: 5-[6-fluoro-4-[[(6-methoxy-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-(6-fluoro-4-(((5-methoxypyridin-2-yl)amino)methyl)-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide; 5-[6-fluoro-4-[[(4-methoxy-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-[4-[[(4-cyclopropyl-2-pyridyl)amino]methyl]-6-fluoro-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-[6-fluoro-4-[[(4-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-(4-(((4,6-dimethylpyridin-2-yl)amino)methyl)-6-fluoro-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide; 5-(6-fluoro-4-(((4-methoxy-5-methylpyridin-2-yl)amino)methyl)-1H-indazol-7-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide; 6-[[6-fluoro-7-(1,1,4-trioxo-1,2,5-thiadiazolidin-2-yl)-1H-indazol-4-yl]methylamino]-4-methyl-pyridine-3-carbonitrile; 5-[6-fluoro-4-[[(4-methoxy-6-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one; 5-[6-Fluoro-4-[[(3-methyl-2-pyridyl)amino]methyl]-1H-indazol-7-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one 1. A compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.

12. 10. A pharmaceutical composition comprising a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

13. 10. A method for treating cancer, comprising administering to a patient a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, wherein the cancer / disease is selected from human carcinoma, epithelial carcinoma, non-epithelial carcinoma, adenocarcinoma, papillary adenocarcinoma, lymphoma, leukemia, melanoma, solid tumor, lymphatic system cancer, kidney cancer, breast cancer, lung cancer, bladder cancer, colon cancer, ovarian cancer, prostate cancer, pancreatic cancer, gastric cancer, brain cancer, head and neck cancer, skin cancer, uterine cancer, testicular cancer, glioma, esophageal cancer, liver cancer including hepatocellular carcinoma, B-cell acute lymphoblastic lymphoma, non-Hodgkin's lymphoma, Burkitt's lymphoma, small cell lymphoma, Hodgkin's lymphoma, leukemia, and multiple myeloma.

14. 10. A method for treating cancer in a patient in need thereof, comprising administering to the patient an effective amount of a compound of claim 1 in combination with another therapeutic agent.

15. 15. The method of claim 14, wherein the additional therapeutic agent is an immunotherapeutic agent.

16. 16. The method of claim 15, wherein the immunotherapeutic agent is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-CTLA-4 antibody.

17. 10. A method for treating cancer in a patient in need of treatment, comprising administering to the patient an effective amount of the pharmaceutically acceptable composition of claim 1.

18. 15. The method of claim 14, wherein the method for treating cancer is selected from radiation therapy, surgery, chemotherapy, or administration of a biopharmaceutical.

19. 19. The method of claim 18, wherein the method for treating the cancer is administering a biopharmaceutical that is an agent that stimulates the immune system.

20. The method according to claim 19, characterized in that an inhibitor of DGKα and / or DGKζ, an antagonist of PD1 / PD-L1, and an antagonist of CTLA4 are administered to the subject.

Images